In ITCC-P4, we provide the world´s
largest repertoire of PDX models of paediatric tumours, available in one place and supported by a comprehensive
dataset of molecular phenotyping and pharmacological characterization corresponding to the original tumour
material and respective PDX.
We have built a large collection of patient derived xenografts (PDX) models across all relevant tumour entities,
including high-risk, relapsed and rare cancers, well representing the paediatric cancer landscape. Each model
has been fully characterized molecularly, pharmacologically, and clinically. This includes RNA & DNA sequencing
as well as methylation profiling and in vivo treatment with standard-of-care drugs (+/- irradiation) and
experimental drugs as well as combinations thereof. Our panel is being continuously enriched over time, with the
in-licensing of new models (including immune-competent mouse models) and continuous improvement of their
annotation and testing information.
Explore our model repertoire and contact us to
discuss your experimental ideas with our experts!